Lyell Immunopharma (LYEL) Accumulated Depreciation & Amortization (2019 - 2025)

Lyell Immunopharma's Accumulated Depreciation & Amortization history runs 7 years deep, the most recent figure standing at $11.5 million for Q4 2025.

• In Q4 2025, Accumulated Depreciation & Amortization fell 41.22% year-over-year to $11.5 million; the TTM figure through Dec 2025 stood at $11.5 million (down 41.22% YoY), while the FY2025 annual figure was $11.5 million, down 41.22% from the prior year.
• Accumulated Depreciation & Amortization came in at $11.5 million for Q4 2025 at Lyell Immunopharma, down from $19.6 million in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $20.2 million in Q4 2023 to a low of $11.5 million in Q4 2025.
• A 5-year average of $16.6 million and a median of $18.0 million in 2022 frame the typical range for Accumulated Depreciation & Amortization.
• Across the five-year window, Accumulated Depreciation & Amortization jumped 217.28% in 2021 and slumped 41.22% in 2025, its largest moves.
• Lyell Immunopharma's Accumulated Depreciation & Amortization stood at $13.6 million in 2021, then soared by 32.27% to $18.0 million in 2022, then climbed by 12.38% to $20.2 million in 2023, then slipped by 3.06% to $19.6 million in 2024, then plunged by 41.22% to $11.5 million in 2025.
• According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $11.5 million, $19.6 million, and $20.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison